Jennifer Humes Biography and Net Worth

Chief Accounting Officer of Roivant Sciences

Jenni joins Roivant with over 20 years of experience and a love of technical accounting. Most recently, she was the Global Investment Banking Controller at JPMorganChase (JPMC) where she led a global team responsible for the accounting, reporting, and internal controls over financial reporting for JPMC’s global banking businesses. Before her time as a Controller, Jenni was in Accounting Policy at JPMC and Citi supporting various Wholesale and Consumer businesses. She began her career in public accounting at PwC and Deloitte spending time in both the auditing and technical accounting advisory practices in Minneapolis, San Diego, London, and New York.

What is Jennifer Humes' net worth?: The estimated net worth of Jennifer Humes is at least $2.45 million as of April 8th, 2026. Ms. Humes owns 84,191 shares of Roivant Sciences stock worth more than $2,452,905 as of April 15th. This net worth approximation does not reflect any other investments that Ms. Humes may own. Learn More about Jennifer Humes' net worth.
How do I contact Jennifer Humes?: The corporate mailing address for Ms. Humes and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347 and via email at [email protected]. Learn More on Jennifer Humes' contact information.
Has Jennifer Humes been buying or selling shares of Roivant Sciences?: Over the course of the past ninety days, Jennifer Humes has sold $384,073.06 in Roivant Sciences stock. Most recently, Jennifer Humes sold 13,538 shares of the business's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a transaction totalling $384,073.06. Following the completion of the sale, the chief accounting officer now directly owns 84,191 shares of the company's stock, valued at $2,388,498.67. Learn More on Jennifer Humes' trading history.
Who are Roivant Sciences' active insiders?: Roivant Sciences' insider roster includes Melissa Epperly (Director), Matthew Gline (CEO), Daniel Gold (Director), Jennifer Humes (Chief Accounting Officer), Rakhi Kumar (CAO), Keith Manchester (Director), Richard Pulik (CFO), Vivek Ramaswamy (Major Shareholder), Mayukh Sukhatme (President and Chief Investment Officer), Frank Torti (Insider), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.
Are insiders buying or selling shares of Roivant Sciences?: In the last year, Roivant Sciences insiders bought shares 2 times. They purchased a total of 16,669,981 shares worth more than $350,049,943.05. In the last year, insiders at the sold shares 55 times. They sold a total of 25,721,436 shares worth more than $507,940,274.82. The most recent insider tranaction occured on April, 8th when CAO Jennifer Humes sold 13,538 shares worth more than $384,073.06. Insiders at Roivant Sciences own 10.8% of the company. Learn More about insider trades at Roivant Sciences.
Information on this page was last updated on 4/8/2026.

Jennifer Humes Insider Trading History at Roivant Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/8/2026	Sell	13,538	$28.37	$384,073.06	84,191

Jennifer Humes Buying and Selling Activity at Roivant Sciences

Roivant Sciences Company Overview

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Today's Range

Now: $29.39

$28.86

$29.49

50 Day Range

MA: $27.68

$21.14

$29.72

2 Week Range

Now: $29.39

$9.90

$30.33

Volume

3,524,399 shs

Average Volume

6,073,241 shs

Market Capitalization

$21.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2